Shanghai Junshi Biosciences (SHA:688180) obtained approval from China's drug administrator to conduct clinical trials for its AWT020 sterile powder for injection.
AWT020 will be carried out as a single drug and in combination with other treatments in patients with advanced malignant tumors, according to a Thursday filing with the Shanghai bourse.
Shares of the pharmaceutical company rose 3% in recent trade on the Shanghai bourse.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.